@article{025a6499049441e9a769c87d454d671a,
title = "Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018",
abstract = "Aim: Patient chart data from the USA during the period of January 2011 through October 2018 were used to assess risk factors for progression in advanced ovarian cancer after response to first-line platinum-based chemotherapy. Patients & methods: Patients with stage III/IV ovarian cancer who completed first-line platinum-based chemotherapy after primary or interval debulking surgery were identified from the Flatiron Health database. Cox proportional hazards modeling was used to assess associations between baseline factors and time to next treatment (TTNT) or overall survival (OS). Results: Patients at stage IV or who received interval debulking surgery had shorter TTNT and OS than patients at stage III or who received primary debulking surgery, respectively. OS was worse in patients with residual disease and in BRCA wild-type. Conclusion: Multiple factors were associated with shorter TTNT or OS in this retrospective real-world analysis.",
keywords = "epithelial ovarian carcinoma, ovarian cancer, ovarian carcinoma, prognosis, risk factors",
author = "Westin, {Shannon N.} and Melinda Louie-Gao and Divya Gupta and Thaker, {Premal H.}",
note = "Funding Information: This study was supported by GlaxoSmithKline. SN Westin funding: NIH SPORE for Ovarian Cancer (P50 CA083639), Andrew Sabin Family Fellowship (no grant number), GOG Foundation Scholar Investigator Award (no grant number), NCI (CA217685 and CA16672). SN Westin reports personal fees from Agenus, GlaxoSmithKline, AstraZeneca, Circulogene, Roche/Genentech, Med-scape, Clovis Oncology, Watermark Research Partners, Gerson Lehrman Group, Vaniam Group, Merck, Pfizer, BioAscend, Novartis, Takeda, Zentalis, Eisai; research support outside the submitted work from ArQule, AstraZeneca, Novartis, Bayer, GlaxoSmithKline, Cotinga Pharmaceuticals, Clovis Oncology, Roche/Genentech. PH Thaker reports personal fees and other from Stryker; personal fees from Celsion, GlaxoSmithKline, Clovis, AstraZeneca, AbbVie, Iovance Biotherapeutics, Genentech, Immunogen, Merck; research support from Merck and GlaxoSmithKline outside the submitted work. M Louie-Gao and D Gupta are current or former employees of GlaxoSmithKline. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funding Information: Medical writing and editorial assistance, funded by GlaxoSmithKline (MA, USA) and coordinated by H Ostendorff-Bach of GlaxoSmithKline, were provided by N Renner and M Kacillas of Ashfield Healthcare Communications (CT, USA) and AM Schreiber of GlaxoSmithKline. Publisher Copyright: {\textcopyright} 2021 Shannon N Westin.",
year = "2021",
month = nov,
doi = "10.2217/fon-2021-0018",
language = "English (US)",
volume = "17",
pages = "4263--4274",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "32",
}